United Therapeutics Stock Investor Sentiment
UTHR Stock | USD 236.93 1.62 0.69% |
Slightly above 59% of all United Therapeutics' retail investors are looking to take a long position. The analysis of the overall investor sentiment regarding United Therapeutics suggests that some traders are interested. United Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in United Therapeutics. The current market sentiment, together with United Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use United Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Panic Vs Confidence
59
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use United Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward United Therapeutics.
News SentimentBullish | Hype SentimentNeutral | Insider SentimentDisposing |
United Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of United daily returns and investor perception about the current price of United Therapeutics as well as its diversification or hedging effects on your existing portfolios.
United Historical Sentiment
Although United Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding United, such as negative comments on social media and news outlets, may cause fear in the market and push United Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of United.
United |
United Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards United Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
United Therapeutics Historical Investor Sentiment
Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
United Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for United Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average United Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on United Therapeutics.
United Therapeutics Maximum Pain Price across 2024-04-19 Option Contracts
United Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of United Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of United Therapeutics' options.
Far too much social signal, news, headlines, and media speculation about United Therapeutics that are available to investors today. That information is available publicly through United media outlets and privately through word of mouth or via United internal channels. However, regardless of the origin, that massive amount of United data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of United Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of United Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to United Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive United Therapeutics alpha.
United Therapeutics Performance against NYSE Composite
Price Growth (%) |
Timeline |
1 | Insider Sell EVP GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics ... | 03/08/2024 |
2 | Disposition of 5955 shares by Martine Rothblatt of United Therapeutics at 237.6187 subject to Rule 16b-3 | 03/14/2024 |
3 | Disposition of 1037 shares by Martine Rothblatt of United Therapeutics at 233.0812 subject to Rule 16b-3 | 03/18/2024 |
4 | Disposition of 15000 shares by Martine Rothblatt of United Therapeutics at 129.49 subject to Rule 16b-3 | 03/19/2024 |
5 | FDA approves Merck lung disease drug acquired in 11B deal | 03/26/2024 |
6 | Disposition of 406 shares by Martine Rothblatt of United Therapeutics at 230.1366 subject to Rule 16b-3 | 04/01/2024 |
7 | Disposition of 1477 shares by Martine Rothblatt of United Therapeutics at 230.5177 subject to Rule 16b-3 | 04/02/2024 |
8 | Disposition of 206 shares by Paul Mahon of United Therapeutics at 234.0889 subject to Rule 16b-3 | 04/04/2024 |
9 | United Therapeutics chairperson and CEO sells over 6.9m in stock | 04/05/2024 |
10 | Disposition of 113 shares by Martine Rothblatt of United Therapeutics at 239.63 subject to Rule 16b-3 | 04/08/2024 |
11 | Disposition of 8006 shares by Martine Rothblatt of United Therapeutics at 237.5172 subject to Rule 16b-3 | 04/09/2024 |
12 | Disposition of 217 shares by Martine Rothblatt of United Therapeutics at 240.78 subject to Rule 16b-3 | 04/11/2024 |
13 | Disposition of 271 shares by Martine Rothblatt of United Therapeutics at 238.8881 subject to Rule 16b-3 | 04/12/2024 |
14 | Disposition of 3000 shares by Raymond Dwek of United Therapeutics at 235.08 subject to Rule 16b-3 | 04/15/2024 |
15 | Hundreds of more apartment units planned for downtown Manchester | 04/16/2024 |
Check out United Therapeutics Hype Analysis, United Therapeutics Correlation and United Therapeutics Performance. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.626 | Earnings Share 19.81 | Revenue Per Share 49.733 | Quarterly Revenue Growth 0.251 | Return On Assets 0.1122 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.